DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Loibl S, Marmé F, Martin M. et al.
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B.
Cancer Res 2021;
81 (Suppl. 04) GS1-02
doi:10.1158/1538-7445.SABCS20-GS1-02
We do not assume any responsibility for the contents of the web pages of other providers.